FH:CC News and Press, FILAMENT HEALTH CORP. From 04/07/22

FILAMENT HEALTH TO PARTICIPATE IN PROMINENT PSYCHEDELIC INVESTOR CONFERENCES IN APRIL 2022 Canada NewsWire VANCOUVER, BC , April 7, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage ...

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire Filament announced FDA approval for the first clinical trial using naturally-sourced psychedelic substances in November 2021 The Company signed multipl...

Filament Health to Participate in the 34th Annual Roth Conference Canada NewsWire VANCOUVER, BC , March 8, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development...

Filament Health and ATMA Journey Centers Announce Licensing Agreement Canada NewsWire ATMA will use Filament's proprietary botanical drug candidate for clinical trials VANCOUVER, BC , Feb. 23, 2022 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO...

FILAMENT HEALTH REFILES Q2 AND Q3 INTERIM FINANCIAL STATEMENTS AND MD&A FILAMENT HEALTH REFILES Q2 AND Q3 INTERIM FINANCIAL STATEMENTS AND MD&A Canada NewsWire VANCOUVER, BC , Feb. 22, 2022 /CNW/ - Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) ...